This Houston-based couple used their own experience of paying down consumer debt to launch a new company. Image courtesy of SpenDebt

Kiley and Ty'Lisha Summers once found themselves nearly $100,000 in debt; now, they have a goal of owning a $100 million company. The Houston-based couple used their own experience of paying down consumer debt to launch SpenDebt, a SaaS payment solution chosen for the Mastercard Start Path program.

You could say debt is ubiquitous in the United States. A 2015 report by The Pew Charitable Trusts found that 80 percent of American households have some form of debt. "As we started sharing our story, we realized that there were so many people who were just like us but didn't know what to do," explains Ty'Lisha, co-founder of SpenDebt.

SpenDebt's model relies on the simple truth: everyone spends money. The company, which is available as a phone app or web service, securely links to the user's bank account and allows you to designate a predetermined micropayment to be deducted at every transaction. The micropayments are then applied monthly to the debt of the user's choice, whether it be lofty student loans or a monthly car payment.

"God gave my husband the vision to start SpenDebt to help people help themselves," she says. Kiley even decided to share his concept Mastercard, but the idea was too early to gain anything other than the corporation's intrigue.

After two years of development and a subsequent year of beta testing, SpenDebt launched its commercialized product in 2019. The Summers applied to Mastercard Start Path, a highly competitive startup engagement program multiple times before being accepted into its 2021 cohort of six scaling startups.

"To finally get the 'yes,' it just made it full circle," says Ty'Lisha. "It's a game changer for SpenDebt."

Ty'Lisha Summers is the co-founder of SpenDebt. Photo courtesy

Fintech is a multibillion-dollar industry, and financial apps have become the darlings of venture capitalism. According to a SpenDebt release, companies that have participated in Start Path have gone on to raise more than $3 billion in post-program capital. Even while investor budgets were trimmed during the pandemic, Fintech companies garnered $44 billion in investments — a 14 percent increase since 2019, reports Finextra.

From the New Statesman to the Raconteur, media outlets and pundits have explored the saturation of the fintech sector. Ty'Lisha is confident that SpenDebt is different from its competitors.

"What's unique is that we give our customers 100 percent control on defining what that micropayment is, unlike our competition where it is strictly just round-up," she explains. The average SpenDebt user has set a $1.70 micropayment, but the co-founders have seen payments set at anything from 50 cents to $25 per transaction.

Initiatives like Bank of America's Keep the Change rounds up each transaction to the nearest dollar amount, then puts that money into a savings account for you to pay your debt off — or not. McKinsey & Company survey reports that more than 50 percent of US consumers expect to spend extra as COVID-19 restrictions relax, with higher-income millennials intending to spend the most. According to CNBC, Gen Z shoppers are also predicted to spend big on niceties like clothing and travel.

Though no app can automate personal discipline, SpenDebt can help you pay down debt and build financial literacy.

"With SpenDebt, once you tell us where you want that payment to go, that's where it's going," explains Ty'Lisha. When the micropayments are deducted from your account, SpenDebt holds onto your accrued payments and sends them monthly to the creditor of your choice. Ty'Lisha notes the service can be canceled or put on hold.

NBC News reported that 46 percent of Americans wiped out their emergency funds in 2020 as they shuffled to make ends meet. States around the country, including Texas, even enacted moratoriums on utility shut-offs in response to the pandemic. In some industries, "businesses went from collecting full payments from people to not collecting anything" or accepting partial payments, she explains.

The pandemic highlighted an opportunity for SpenDebt to partner with enterprises to offer creative solutions for payments that help customers pay off existing debt while helping businesses collect "something versus nothing."

As SpenDebt includes enterprises in its long-term growth strategy, the company founders have also pledged to work with nonprofits.

For the Summerses, SpenDebt's mission surpasses their desire to live a debt-free life. "As a part of our debt-free journey, we couldn't help but become more well-versed in finances. We were on a quest to make our money work for us versus the other way around," shares Ty'Lisha.

As Black business owners, Kiley and Ty'Lisha want to focus on building generational wealth for their family's future and help SpenDebt users do the same. "We like to say that we want all of the generational curses that may have been passed down to us to stop with us, and to start creating generational wealth for our future," she explains.

"[Debt] doesn't just address the middle class; there are so many people across the spectrum in debt," says Ty'Lisha. "A lot of times, the low-to-moderate income communities get overlooked," she continues.

SpenDebt is a preferred partner of United Way of Greater Houston and recently penned a partnership with Impact Hub Houston — an incubator with a mission to empower entrepreneurs and small businesses to take on issues like sustainability, gender equality, and economic growth.

SpenDebt hopes to capture its first enterprise customer during its six-month StartPath program and hopes to one day become a $100 billion company. "The resources, the network, the knowledge that we're getting from Mastercard and their network, the exposure that we're getting—it's going to be huge," says Ty'Lisha.

Of the many goals for SpenDebt's future, she wants the company to be "a solution for communities that may have been overlooked."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston startups named most innovative in Texas by LexisNexis

report card

Three Houston companies claimed spots on LexisNexis's 10 Most Innovative Startups in Texas report, with two working in the geothermal energy space.

Sage Geosystems claimed the No. 3 spot on the list, and Fervo Energy followed closely behind at No. 5. Fintech unicorn HighRadius rounded out the list of Houston companies at No. 8.

LexisNexis Intellectual Property Solutions compiled the report. It was based on each company's Patent Asset Index, a proprietary metric from LexisNexis that identifies the strength and value of each company’s patent assets based on factors such as patent quality, geographic scope and size of the portfolio.

Houston tied with Austin, each with three companies represented on the list. Caris Life Sciences, a biotechnology company based in Dallas, claimed the top spot with a Patent Asset Index more than 5 times that of its next competitor, Apptronik, an Austin-based AI-powered humanoid robotics company.

“Texas has always been fertile ground for bold entrepreneurs, and these innovative startups carry that tradition forward with strong businesses based on outstanding patent assets,” Marco Richter, senior director of IP analytics and strategy for LexisNexis Intellectual Property Solutions, said in a release. “These companies have proven their innovation by creating the most valuable patent portfolios in a state that’s known for game-changing inventions and cutting-edge technologies.We are pleased to recognize Texas’ most innovative startups for turning their ideas into patented innovations and look forward to watching them scale, disrupt, and thrive on the foundation they’ve laid today.”

This year's list reflects a range in location and industry. Here's the full list of LexisNexis' 10 Most Innovative Startups in Texas, ranked by patent portfolios.

  1. Caris (Dallas)
  2. Apptronik (Austin)
  3. Sage Geosystems (Houston)
  4. HiddenLayer (Austin)
  5. Fervo Energy (Houston)
  6. Plus One Robotics (San Antonio)
  7. Diligent Robotics (Austin)
  8. HighRadius (Houston)
  9. LTK (Dallas)
  10. Eagle Eye Networks (Austin)

Sage Geosystems has partnered on major geothermal projects with the United States Department of Defense's Defense Innovation Unit, the U.S. Air Force and Meta Platforms. Sage's 3-megawatt commercial EarthStore geothermal energy storage facility in Christine, Texas, was expected to be completed by the end of last year.

Fervo Energy fully contracted its flagship 500 MW geothermal development, Cape Station, this spring. Cape Station is currently one of the world’s largest enhanced geothermal systems (EGS) developments, and the station will begin to deliver electricity to the grid in 2026. The company was recently named North American Company of the Year by research and consulting firm Cleantech Group and came in at No. 6 on Time magazine and Statista’s list of America’s Top GreenTech Companies of 2025. It's now considered a unicorn, meaning its valuation as a private company has surpassed $1 billion.

Meanwhile, HighRadius announced earlier this year that it plans to release a fully autonomous finance platform for the "office of the CFO" by 2027. The company reached unicorn status in 2020.

---

This article originally appeared on Energy Capital HTX.

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.